17 October 2025 in Clinical Cancer Research
Purpose: Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and is characterized by poor survival rates and high recurrence after surgery. Glypican-3 (GPC3) is a proteoglycan highly expressed in HCC but absent in most normal tissue, making it an attractive diagnostic and therapeutic target. In this study, we introduce a second-generation GPC3-targeted single-domain antibody probe (ssHN3) bearing a positron-emitting isotope fluorine-18 (18F), ssHN3-Al[18F]F-RESCA (Al[18F]F-ssHN3), for HCC-selective PET imaging. In addition, we show its use as a functional imaging agent following focal tumor thermal ablation. Experimental Design: Site-specific conjugation was used to synthesize the nanobody-based PET (immunoPET) probe ssHN3-Al[18F]F-RESCA. Binding affinity was determined using biolayer interferometry, and in vivo PET/CT imaging and biodistribution studies were performed in three liver cancer models with varying GPC3 expression (HepG2 > Hep3B > Huh7). Mice inoculated with HepG2 orthotopic liver tumors were also imaged before and 1 week after thermal tumor ablation to assess response. Results: Our agent exhibited high purity (>98%), nanomolar affinity for GPC3, and tumor uptake corresponding to GPC3 expression on PET/CT and biodistribution studies. In orthotopic murine models of liver cancer, Al[18F]F-ssHN3 successfully distinguished between total versus subtotal thermal ablation, accurately identifying residual, viable disease. Conclusions: We successfully designed, engineered, and tested a GPC3-targeted 18F-labeled nanobody immunoPET agent, Al[18F]F-ssHN3, demonstrating that it can be used for same-day diagnostic imaging in murine models of liver cancer. Importantly, this agent could address the limitations of current imaging methods by detecting residual disease after thermal ablation and other locoregional therapies.
15 May 2025 in Communications Engineering
Autoradiography is used to study the distribution and binding of radioisotope tagged ligands in tissue at microscale among other applications. The technology has evolved since its inception when it used analogue film exposure techniques with the introduction of digital imaging systems sensitive to ionizing radiation. We report on the development of our Quantitative Particle Identification spectral autoradiography system (QPID), which is based on the Timepix3 sensor and a gamma detecting scintillation crystal. This autoradiography system leverages the ionizing radiation detection features of the Timepix3 to measure the energy deposition from charged particles from radioisotopes with a time resolution of 7.7 ns full width at half max (FWHM), generating spectral or activity autoradiography images. The QPID includes a scintillation crystal used to record gamma emissions coincident with the Timepix3 ionization events with a time resolution of 24.2 ns FWHM. The QPID can separate tracks between α and ß particles, select specific ranges of deposited energies or select on the presence of coincident gamma emissions within a selected energy range when generating images. The QPID has a 10% linearity response up to 700 Bq for 223Ra and 2.5 kBq for 18 F radioisotopes. Using α and ß+ particle identification filters, separate images of 223RaCl2 and Na18F activity distributions were generated from a bone sample infused with the two radioligands together. This unique capability can open the door to the study of targeted radiotherapies which use theranostic α and ß+ imaging agents by measuring their relative pharmacokinetic properties.
5 March 2023 in Seminars in Nuclear Medicine
3 July 2026 in Science Advances
B7-H4 is an emerging immunoregulatory checkpoint broadly overexpressed across solid tumors and minimally present in normal tissues, making it an attractive candidate for targeted imaging and therapy. Here, we develop and evaluate a B7-H4–directed radiotheranostic antibody labeled with [ 89 Zr] for PET imaging and with either [ 177 Lu] or [ 225 Ac] for β- or α-particle therapy, respectively. [ 89 Zr]-immunoPET enabled quantitative, whole-body visualization of B7-H4 expression and reliably distinguished high, intermediate, and negative-expressing tumors. Radiotherapy with [ 177 Lu]- or [ 225 Ac]-conjugated antibody exhibited potent, antigen-dependent antitumor activity, including complete and durable regressions in B7-H4–high expressing xenografts after a single administration, while having a minimal effect on B7-H4–negative tumors. Both therapeutic constructs were well tolerated, causing only transient, reversible myelosuppression without sustained hepatic, renal, or histopathologic toxicity. These findings identify B7-H4 as a promising target for integrated imaging and radionuclide therapy and provide a preclinical foundation for the future development of B7-H4–directed radiotheranostic strategies.
29 July 2026 in Cancer Research
Small cell lung cancer (SCLC) remains one of the most lethal malignancies, with a 5-year survival of <10% despite advances in treatment. Seizure-related gene 6 (SEZ6), a type I transmembrane protein preferentially expressed in neuroendocrine tumors, has recently emerged as a promising therapeutic target, supported by clinical activity of SEZ6-targeted antibody–drug conjugates in relapsed SCLC. In this study, we developed and evaluated a humanized anti-SEZ6 monoclonal antibody for SEZ6-targeted positron emission tomography imaging and α-particle radioimmunotherapy. Immunohistochemistry of patient tissues confirmed strong, stage-independent SEZ6 expression. Cell-based studies demonstrated high SEZ6 receptor densities, supporting high-affinity antibody binding and rapid receptor-mediated internalization. [89Zr]Zr-DFO-SEZ6-Ab administered at low antibody mass exhibited rapid hepatosplenic clearance with minimal tumor uptake despite high intratumoral levels. This pattern was consistent with active ectodomain shedding and local accumulation of soluble antigen within the tumor microenvironment, creating an extracellular antigen sink and limiting effective target engagement. Increasing the antibody mass overcame this barrier, dramatically increasing tumor uptake in xenografts. Treatment with [225Ac]Ac-Macropa-SEZ6-Ab induced complete tumor regression, whereas coadministration of the ATR inhibitor berzosertib enhanced efficacy at lower radioactivity doses without added toxicity. Together, these findings identify tumor-localized SEZ6 shedding as a biological barrier to SEZ6-targeted therapy, define dosing strategies to overcome it, and demonstrate potent antitumor activity of SEZ6-directed α-particle radioimmunotherapy in SCLC. Significance: Dosing strategies that overcome antigen sink effects induced by a tumor-localized ectodomain shedding enable SEZ6-based imaging and theranostics in small cell lung cancer.
17 November 2023 in bioRxiv
Advanced prostate cancer is treated with androgen receptor (AR) signaling inhibitors, which are initially effective, but most patients eventually develop resistance and progress to castrate-resistant prostate cancer (CRPC). Loss of RB1 in CRPC tumors is correlated with rapid progression and poor patient survival and, in combination with TP53 loss, predisposes patients to the development of transitional neuroendocrine prostate cancer (NEPC). Although progressive CRPC is clinically associated with higher 18FDG-PET SUVmax values, it is unknown whether inactivation of RB1 and/or TP53 is a driver of increased glucose import. Using a cohort of patient-derived xenograft (PDX)-derived CRPC organoids, we found that NEPC could not be conclusively distinguished from adenocarcinoma by 18FDG uptake alone, and PSMA protein levels did not correlate with cancer phenotype or 18FDG uptake. Castration-resistant models showed higher 18FDG uptake, but lower pyruvate-to-lactate conversion compared to their castration-sensitive counterparts. In parallel studies using castration-sensitive prostate cancer models, RB1/TP53 knockdown did not affect 18FDG uptake, but increased basal respiration and glycolytic activity, with combined depletion leading to glucose diversion into glycogenesis. These metabolic changes were reflected in increased lactate dehydrogenase flux detected by 13C-hyperpolarized magnetic resonance spectroscopy upon RB1 loss, but not in 18FDG uptake. The metabolic heterogeneity revealed here suggests that a multimodal molecular imaging approach can improve tumor characterization, potentially leading to a better prognosis in cancer treatment.